Centiva Capital, LP Immunity Bio, Inc. Transaction History
Centiva Capital, LP
- $4.79 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding IBRX
# of Institutions
204Shares Held
70MCall Options Held
1.64MPut Options Held
1.31M-
Vanguard Group Inc Valley Forge, PA16.9MShares$49.7 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$33.6 Million0.0% of portfolio
-
State Street Corp Boston, MA8.65MShares$25.4 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.85MShares$11.3 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.25MShares$6.61 Million0.0% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $1.18B
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...